Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
9/28/26
Ligand Pharmaceuticals (LGNDZ)
Monday
1:31 AM
ThesisLigand Pharmaceuticals: the story is balanced — Partner pipeline progression - FDA approvals or Phase 3 trial results for programs using Ligand technologies trigger…
★ Analysts see FY2027 revenue reaching $385M — +32.7% growth in a single year.
What Moves the Stock
01Partner pipeline progression - FDA approvals or Phase 3 trial results for programs using Ligand technologies trigger milestone payments and future royalty streams
02New licensing agreements - Announcements of technology partnerships with upfront fees and potential milestone/royalty terms
03Royalty revenue growth from existing commercial products - Quarterly sales performance of key royalty-generating drugs like Kyprolis (multiple myeloma)
04M&A activity - Acquisitions of additional royalty portfolios or technology platforms to expand revenue base
05Partner company developments - Commercial success or setbacks at major partners (Amgen, Takeda, Merck, others) directly impact royalty flows
06Royalty revenue from commercial products using Captisol solubilization technology and OmniAb antibody platforms (estimated 60-70% of revenue)
07License fees and milestone payments from new technology partnerships and development stage achievements (estimated 20-30%)
08Material sales of Captisol enabling formulation to pharmaceutical partners (estimated 10-15%)
growth - Investors are attracted to the high-margin, asset-light royalty model with potential for compounding cash flows as partner pipeline…
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for long-duration…
Watch on earnings: Quarterly royalty revenue by product and therapeutic area to track commercial portfolio performance, Number of partner programs in Phase 2/3 trials and regulatory review as leading indicators of future milestone payments, New licensing deal announcements with disclosed economics (upfront fees, milestone potential, royalty rates).
One Sentence Summary:
Ligand Pharmaceuticals: the story is balanced — partner pipeline progression - fda approvals or phase 3 trial results for programs using ligand technologies trigger milestone payments.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
